الفهرس 
Genetic influences on cognition in idiopathic parkinson{u2019}s disease
ContentsOnly 14 pages are availabe for public view
 |  | from | 254 |  |  |
| | | from | 254 | | |
Abstract
Introduction: Parkinson disease (PD) has been recently recognized as a disease that encompasses more than just nigrostriatal degeneration.Estimates of dementia prevalence in PD vary, depending on the population studied, but increase with disease duration. variations in apolipoprotein E (APOE) and microtubule-associated protein tau (MAPT) genotypes are associated with cognitive decline in PD. Apoliporotein E (APOE) and microtubule-associated protein tau (MAPT), are of particular interest because of their known association with dementia in other neurodegenerative diseases, such as Alzheimer{u2019}s disease (AD) and atypical parkinsonian syndromes. Aim of the work: to study the role of genetic variations (apolipoprotein E (APOE) and microtubule-associated protein tau (MAPT) genotypes) in cognitive impairment in patients with idiopathic Parkinson’s disease. Methodology: This study included 50 patients fulfilled the criteria for diagnosis of idiopathic Parkinson’s disease based on British Brain Bank criteria. Results: A statistical significance was found between change in UPDRS III (motor) and side of symptoms onset being significant on right side but, No statistical significance was found between change in UPDRS III and type of symptoms onset or predominent type of symptoms.Regarding clinical symptoms, A statistical significance was found between change in UPDRS and ApoE f4 carrier/non carrier being worse with ApoE f4 carrier but, no statistical significance was found between change in UPDRS and MAPT haplotypes. Conclusion:The cognitive performance and motor functions was better in ApoE f4 carriers patients in group I than in group II. The cognitive performance and motor functions was better in MAPT H1/H1 haplotype patients in group I than in group II.Carriers of both ApoEf4 & MAPT H1/H1 have worset cognitive and clinical performance than other PD patients